Coix seed lipid nanoparticle capable of loading nucleic acid medicine as well as preparation method and application of coix seed lipid nanoparticle
Through the composition of coix seed lipid nanoparticles combined with DOTAP and DOPE and γ-PGA modification, the heterogeneity and drug resistance of pancreatic cancer cells to drug delivery are solved, and efficient nucleic acid drug delivery and targeted treatment are achieved, which significantly Improves the therapeutic effect.
Patent Information
- Application Number
- CN202411206204.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-30
- Publication Date
- 2024-12-06
AI Technical Summary
The high heterogeneity and drug resistance of pancreatic cancer cells lead to poor delivery and treatment effects of existing drugs, and the existing lipid nanoparticles are inefficient in escape in lysosomes, are easily affected by degradation, and are difficult to effectively deliver nucleic acid drugs.
Lipid nanoparticles using coix seed lipid as the main component, through appropriate composition and surface modification, the stability of the nanoparticles and the ability of intracellular lysosomes are improved, combined with DOTAP and DOPE to form cationic lipid nanoparticles, and γ is used. -PGA performs charge reversal modification to promote cellular uptake in the pancreatic cancer microenvironment.
It significantly improves the transfection efficiency and utilization of nucleic acid drugs, realizes targeted delivery of pancreatic cancer cells, effectively knocks down the expression of target genes and proteins, and significantly improves the therapeutic effect.
Smart Images

Figure CN119074688A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of medical technology, and in particular to coix seed lipid nanoparticles capable of loading nucleic acid drugs, and a preparation method and application thereof. Background Art
[0002] Pancreatic cancer is a common, highly malignant digestive system tumor characterized by high malignancy and complex microenvironment. The high heterogeneity and drug resistance of pancreatic cancer cells seriously hinder drug delivery and treatment. Currently, the main treatments for pancreatic cancer include surgery and chemoradiotherapy. Surgery is the preferred treatment for early pancreatic cancer, but the surgical resection rate is low and there is still a recurrence rate of up to 80%. Pancreatic cancer is highly resistant to conventional chemotherapy drugs, and chemotherapy has strong side effects on tumors and a short duration of treatment, resulting in poor treatment effects. Therefore, it is necessary to find new therapies with effective anti-cancer effects and fewer side effects to fight pancreatic cancer.
[0003] In recent years, gene therapy has made many breakthroughs. Gene drugs, including DNA drugs and RNA drugs, are mostly used for cancer treatment. Among them, small interfering RNA (siRNA) has attracted much attention as a potential cancer treatment drug. However, due to the influence of multiple active enzymes in the body and the insufficient permeability of siRNA itself, it is necessary to construct a suitable delivery carrier to ensure its stability and effectiveness in the body.
[0004] Lipid nanoparticles (LNPs) are currently the most promising non-viral gene delivery system in clinical practice. Lipid nanoparticles carry positively charged lipids that can tightly bind to negatively charged nucleic acid drug molecules. Lipid nanoparticles mainly enter cells through macropinocytosis and clathrin-mediated endocytosis, and then fuse with lysosomes, but the efficiency of lipid nanoparticles escaping from lysosomes is relatively low and they are easily affected by lysosomal degradation. Given that nucleic acid drug molecules must reach the cytoplasm to exert their therapeutic effects, lysosomal escape is crucial for the activity of lipid nanoparticle-nucleic acid drug molecules. Compared with the components of traditional lipid nanoparticles, the anti-tumor active lipid components of traditional Chinese medicine have unique advantages over traditional Chinese medicine components, and can form multi-target, stable and easily available carriers, while promoting immune activation and synergistic intervention. Coix seed oil (CSO) is the main component of the traditional Chinese medicine coix seed, which is a 2,3-butanediol ester of unsaturated fatty acids. It has been proven to have anti-tumor, antioxidant, and immune-enhancing effects. Many studies have shown that using coix seed lipid as a lipid component can obtain a safe, effective and stable delivery carrier, which can achieve lysosomal escape in cells and synergize with other drugs to exert anti-tumor effects. At present, there are no reports on lipid nanoparticles with coix seed lipid as the main component.
[0005] Since the cell membrane surface of pancreatic cancer microenvironment cell subpopulations, such as vascular endothelial cells, fibroblasts, adipocytes, and tumor cells, has highly expressed glutamyl transpeptidase GGT receptors. Studies have shown that the surface modification of positively charged polycation polylysine hydrobromide and negatively charged polyanion polyglutamate sodium salt (γ-PGA) can be used to prepare charge reversal preparations. By utilizing the highly expressed GGT receptors on the cell membrane of pancreatic cancer microenvironment cell populations to shear γ-PGA, the surface of the preparation can be positively charged, which promotes its uptake in the tumor microenvironment. Summary of the invention
[0006] The purpose of the present invention is to provide a coix seed lipid nanoparticle capable of loading a nucleic acid drug, a preparation method and a use thereof in view of the deficiencies in the prior art.
[0007] The objective of the present invention is achieved through the following technical solutions:
[0008] A method for preparing coix seed lipid nanoparticles capable of loading nucleic acid drugs comprises the following steps:
[0009] Weighing an oil phase and an aqueous phase, wherein the oil phase comprises 63.6-736.0 mg of coix seed fat, 15.2-47.0 mg of DOTAP and 2.5-28.0 mg of DOPE, and the aqueous phase comprises 4 mL of pure water and 90 mg of glycerol; stirring the oil phase and the aqueous phase at 70° C. to completely dissolve them, slowly dripping the aqueous phase into the oil phase and mixing them by magnetic stirring to form an emulsion, homogenizing the emulsion at room temperature with a high-speed homogenizer for 1-10 min, and ultrasonicating with an ultrasonic emulsifier for 1-5 min to obtain coix seed fat lipid nanoparticles;
[0010] Disclosed is coix seed lipid nanoparticle capable of loading nucleic acid drugs. The coix seed lipid nanoparticle consists of an oil phase and an aqueous phase, wherein the oil phase comprises 63.6-736.0 mg coix seed lipid, 15.2-47.0 mg DOTAP and 2.5-28.0 mg DOPE, and the aqueous phase comprises 4 mL pure water and 90 mg glycerol.
[0011] Furthermore, the coix seed fat lipid nanoparticles are composed of an oil phase and an aqueous phase, wherein the oil phase includes 313 mg coix seed fat, 33 mg DOTAP and 11 mg DOPE, and the aqueous phase includes 4 mL pure water and 90 mg glycerol.
[0012] The present invention also provides a use of coix seed lipid nanoparticles capable of loading nucleic acid drugs in treating pancreatic cancer.
[0013] The beneficial effects of the present invention are:
[0014] 1. The preparation method of the coix seed lipid nanoparticles constructed by the present invention, the nanocarrier can be used for nucleic acid drug delivery, significantly improving the transfection efficiency of nucleic acid drug molecules in vivo, and has the same effect as the commercially available reagent Lipofectamine RNAiMAX.
[0015] 2. The coix seed lipid nanoparticles constructed by the present invention have coix seed ester, a lipid component of traditional Chinese medicine, as the main component and have natural lipid droplet targeting. After the carrier delivers siRNA into the cell through endocytosis, it can achieve lysosomal escape and then target the lipid droplet site, thereby improving drug utilization.
[0016] 3. After the coix seed lipid nanoparticles constructed by the present invention deliver nucleic acid drug molecules into cells, they can effectively knock down the expression of target genes and proteins, inhibit the proliferation of pancreatic cancer cells, have specific tumor targeting in animals, and the carriers are enriched in the tumor site, which has significant delivery advantages. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1 is a scanning electron micrograph of the coix seed lipid nanoparticles prepared in Example 5;
[0018] Figure 2 is a scanning electron micrograph of PGA-LNP prepared in Example 7;
[0019] Figure 3 It is a schematic diagram of the gel retardation test results of lipid nanoparticle / nucleic acid drug molecule complexes at different N / P ratios;
[0020] Figure 4 is the uptake diagram of different preparations in AsPC-1 cells;
[0021] Figure 5 This is the co-localization result of different preparations in lipid droplets of AsPC-1 cells;
[0022] Figure 6 This is the result of co-localization of different preparations in lysosomes of AsPC-1 cells;
[0023] Figure 7 Different formulations encapsulate siKRAS G12D , Schematic diagram of the effect of siNC on the proliferation of AsPC-1 and BxPC-3 cells;
[0024] Figure 8 Different formulations encapsulate siKRAS G12D , Statistical graph of crystal violet absorbance of siNC on AsPC-1 and BxPC-3 cells;
[0025] Fig. 9 Different formulations encapsulate siKRAS G12D, siNC on KRAS in AsPC-1 cells G12D Schematic diagram of the effects of mRNA;
[0026] Fig.10 Different formulations encapsulate siKRAS G12D , siNC on KRAS in AsPC-1 cells G12D Schematic diagram of the effects of proteins;
[0027] Fig.11 is the ex vivo fluorescence images of tumors and tissues after lipid nanoparticles were placed in the body for 6, 12, and 24 hours;
[0028] Fig.12 It is the statistical graph of the mean fluorescence intensity of tumors and tissues of lipid nanoparticles in vivo at 6, 12 and 24 hours. DETAILED DESCRIPTION
[0029] In order to make the content of the invention easier to understand, the technical solution of the present invention is further described below in conjunction with specific implementation methods, but the present invention is not limited thereto.
[0030] The present invention provides a method for preparing coix seed lipid nanoparticles capable of loading nucleic acid drugs, comprising the following steps:
[0031] 1. Preparation and characterization of coix seed lipid nanoparticles.
[0032] 1.1. Weigh the oil phase and the water phase, wherein the oil phase comprises 63.6-736.0 mg of coix seed fat, 15.2-47.0 mg of DOTAP and 2.5-28.0 mg of DOPE, and the water phase comprises 4 mL of pure water and 90 mg of glycerol; stir the oil phase and the water phase at 70° C. to completely dissolve them, slowly drip the water phase into the oil phase and mix them by magnetic stirring to form an emulsion, homogenize the emulsion at room temperature with a high-speed homogenizer for 1-10 min, and ultrasonicate with an ultrasonic emulsifier for 1-5 min to obtain coix seed fat lipid nanoparticles.
[0033] 1.2. Weigh PGA and dissolve it in deionized water to prepare a solution with a concentration of 0.2-2 g / L. Take 1 mL of PGA solution of different concentrations in a round-bottom flask, drop 0.1-0.4 mL of cationic nanoparticles into the PGA solution, and stir magnetically for 5 minutes to obtain PGA-LNP lipid nanoparticles. PGA-LNP was stored in a refrigerator at 4°C.
[0034] 1.3. Dilute the coix seed lipid nanoparticle solution with deionized water at a volume ratio of 1:300, and place it in a Malvern particle size analyzer to detect the particle size, potential and PDI; dilute the coix seed lipid nanoparticles 100 times with deionized water, drop them onto the copper mesh covered with a carbon film, evaporate them naturally, negatively stain them with 2% phosphotungstic acid, and observe and photograph them using a transmission electron microscope.
[0035] 2. Detect the binding ability of coix seed lipid nanoparticles with nucleic acid drug molecules.
[0036] Through agarose gel electrophoresis experiment, the coix seed lipid nanoparticles and KRAS G12D The N / P ratio of siRNA or NCsiRNA is 0.5:1-2:1 to form a lipid nanoparticle / siRNA complex. The sample is added to an agar gel plate. The electrophoresis conditions are 120V, 400mA, and the electrophoresis is 10-15min. The gel is developed using gel imaging and photographed to observe that the optimal N / P of coix seed lipid nanoparticles and siRNA is 2:1.
[0037] 3. Conduct cell uptake experiments.
[0038] First, the FAM-siRNA-labeled lipid nanoparticle / siRNA complex was used to prepare the Lipo / FAM-siRNA complex according to the instructions; then AsPC-1 cells in the logarithmic growth phase were taken and 10 cells were added to each well. 4 The cells were inoculated at a density of 100 cells / mL in a cell slide and cultured in an incubator for 24 hours. Opti-MEM culture medium, free FAM-siRNA, PGA-LNP / FAM-siRNA or Lipo / FAM-siRNA culture medium were then added to the slide, each containing 200 nM siRNA. The slides were incubated in a cell culture incubator for 6 hours before treatment. Finally, laser confocal microscopy was used to observe the cellular uptake of FAM-siRNA. The fluorescence signal values of the LNP / FAM-siRNA and Lipo / FAM-siRNA groups were close, and were significantly higher than those of the free FAM-siRNA group, indicating that the transfection efficiency of lipid nanoparticles and Lipo was similar.
[0039] 4. Conduct cell lipid droplet co-localization experiments.
[0040] First use BODIPY TM C 12 Labeled lipid droplets were stained with 5 μM BODIPY TM C 12The culture medium was stained for 16 hours and then discarded; the coix seed lipid nanoparticle solution was then mixed with DEPC water and placed at room temperature for 30 minutes, and the culture medium of free FAM-siRNA, PGA-LNP / FAM-siRNA or Lipo / FAM-siRNA was diluted with Opti-MEM culture medium, and the final concentration of FAM-siRNA was 200nM; finally, the above solution was co-cultured with cells at 37°C for 6 hours and 12 hours, and laser confocal microscopy was used for observation. LNP / FAM-siRNA achieved lipid droplet co-localization at 12 hours, and the vector can be targeted to the lipid droplet site.
[0041] 5. Conduct lysosomal escape experiments.
[0042] Lyso-Tracker Red dye was used to label intracellular lysosomes, and the culture medium of free FAM-siRNA, LNP / FAM-siRNA or Lipo / FAM-siRNA was co-cultured with cells at 37°C for 6 h and 12 h, respectively. The results were observed under a laser confocal microscope. 12 h after administration of LNP / FAM-siRNA, green fluorescence appeared at the position pointed by the arrow when the fluorescence overlapped, indicating that the vector escaped from the lysosome and entered the cytoplasm. Therefore, the Lipo / FAM-siRNA group could not achieve lysosomal escape at 12 h.
[0043] 6. Detection of clone formation experiments to detect the effects of lipid nanoparticles / nucleic acid drug molecules on cell proliferation.
[0044] Using KRAS G12D Design of siKRAS as a target gene G12D , blank culture medium, LNP / siKRAS G12D 、LNP / siNC、Lipo / siKRAS G12D and Lipo / siNC, 1 mL of each was added to different wells for transfection. After 6 hours of administration, the culture medium was discarded, and fresh drug-free culture medium was added to continue culturing for 14 days, and the culture medium was replaced every 3 days. After the formation of visible colonies, the old culture medium was discarded and the cells were washed 3 times with PBS, fixed with 4% PFA for 10 minutes, and 1 mL of 0.1% crystal violet dye was added to each well for staining for 10 minutes. The cells were washed several times with PBS, dried and photographed with a scanner. G12D Lipid nanoparticles can effectively deliver siKRAS to inhibit the proliferation of AsPC-1 cells G12D And exert therapeutic effect.
[0045] 7. Detection of intracellular KRAS using qRT-PCR G12D of gene expression.
[0046] Prepare blank culture medium, LNP / siKRAS G12D 、LNP / siNC、Lipo / siKRAS G12D 1 mL of each was added to different well plates for transfection. After 6 h of administration, the medium was discarded and fresh medium without drug was added to continue culturing for 42 h. The medium containing drug was discarded and RNA of each group was extracted according to the qRT-PCR method to detect intracellular KRAS G12D Gene expression, LNP / siKRAS G12D Lipo / siKRAS G12D It can effectively transfect AsPC-1 cells, promote the release of nucleic acid drug molecules in cells and exert a silencing effect.
[0047] 8. Detection of intracellular KRAS using Western blot G12D protein expression.
[0048] Prepare blank culture medium, LNP / siKRAS G12D 、LNP / siNC、Lipo / siKRAS G12D 1 mL of each was added to different well plates for transfection. After 6 h of administration, the medium was discarded and fresh medium without drug was added to continue culturing for 42 h. The medium containing drug was discarded and each group of proteins was extracted according to the Western blot method to detect intracellular KRAS G12D Protein expression, LNP / siKRAS G12D Lipo / siKRAS G12D The knockdown effect of G12D Protein expression.
[0049] 9. Use in vivo fluorescence imaging to investigate the targeting effect of PGA-LNP / FAM-siRNA in nude mice.
[0050] To enhance the tumor targeting of lipid nanoparticles in vivo, the charge-reversed preparation PGA-LNP was prepared by surface modification with negatively charged polyanion polyglutamate sodium salt γ-PGA; γ-PGA was sheared by utilizing the GGT receptor highly expressed on the cell membrane in the pancreatic cancer microenvironment cell population, so that the surface of the preparation was positively charged, promoting its uptake in the tumor microenvironment; an in situ tumor-bearing nude mouse model was constructed, and 18 successfully modeled tumor-bearing nude mice were randomly selected and divided into 6 groups, with 3 mice in each group; FAM-siRNA or PGA-LNP / FAM-siRNA solution was injected intraperitoneally at a siRNA dose of 2 nmol / time, and the mice were placed in a small animal in vivo imager at 6, 12, and 24 hours after administration, respectively, to detect the FAM fluorescence signal. Lipid nanoparticles can significantly enhance the tumor targeting and in vivo retention time of nucleic acid drug molecules.
[0051] Embodiment 1:
[0052] The oil phase (400 mg of coix seed fat, 32 mg of DOTAP and 16 mg of DOPE) and the aqueous phase (4 mL of pure water and 90 mg of glycerol) were weighed and stirred at 70°C for complete dissolution. The aqueous phase was slowly dropped into the oil phase and mixed by magnetic stirring to form an emulsion. The prepared emulsion was homogenized in a high-speed homogenizer at room temperature for 1, 5 and 10 minutes respectively, and ultrasonically emulsified in an ultrasonic emulsifier for 5 minutes to obtain coix seed fat lipid nanoparticles.
[0053] Table 1: Particle size determination of lipid nanoparticles prepared at different homogenization times
[0054] Homogenization time (min) Particle size (nm) PDI 1 270.2±1.6 0.16 5 229.2±1.8 0.12 10 237.0±2.6 0.14
[0055] As can be seen from the above table, in Example 1, the homogenization time of the high-speed homogenizer was changed to prepare coix seed lipid nanoparticles. According to the particle size, the optimal preparation condition was homogenization with a high-speed homogenizer for 5 minutes for subsequent research.
[0056] Embodiment 2:
[0057] The oil phase (400 mg of coix seed fat, 32 mg of DOTAP and 16 mg of DOPE) and the aqueous phase (4 mL of pure water and 90 mg of glycerol) were weighed and stirred at 70°C for complete dissolution. The aqueous phase was slowly dropped into the oil phase and mixed by magnetic stirring to form an emulsion. The prepared emulsion was homogenized in a high-speed homogenizer for 5 min at room temperature and ultrasonically emulsified in an ultrasonic emulsifier for 1, 3 and 5 min respectively to obtain coix seed fat lipid nanoparticles.
[0058] Table 2: Particle size determination of lipid nanoparticles prepared at different ultrasonic times
[0059] Ultrasonic time (min) Particle size (nm) PDI 1 378.2±9.9 0.34 3 221.7±3.8 0.15 5 227.5±3.0 0.20
[0060] As can be seen from the above table, in Example 2, the ultrasonic time of the ultrasonic emulsifier was changed to prepare coix seed lipid nanoparticles. According to the particle size, the optimal preparation condition was ultrasonic emulsifier ultrasonic time of 3 minutes for subsequent research.
[0061] Embodiment 3:
[0062] The oil phase (63.6, 313.0 and 736.0 mg of coix seed fat, 32.0 mg of DOTAP and 16.0 mg of DOPE, respectively) and the aqueous phase (4 mL of pure water and 90 mg of glycerol) were weighed and stirred at 70°C to completely dissolve. The aqueous phase was slowly dropped into the oil phase and mixed by magnetic stirring to form an emulsion. The prepared emulsion was homogenized in a high-speed homogenizer for 5 min at room temperature and ultrasonically emulsified for 3 min to obtain coix seed fat lipid nanoparticles.
[0063] Table 3: Particle size determination of lipid nanoparticles prepared with different weights of coix seed fat
[0064] Coix seed fat (mg) Particle size (nm) PDI 63.6 251.3±2.9 0.18 313.0 183.6±2.7 0.18 736.0 333.9±5.4 0.20
[0065] As can be seen from the above table, in Example 3, the weight of coix seed fat in the oil phase was changed to prepare coix seed fat lipid nanoparticles, and the preferred oil phase formula condition was coix seed fat 313.0 mg according to the particle size for subsequent research.
[0066] Embodiment 4:
[0067] The oil phase (313.0 mg of coix seed fat, 15.2, 33.0 and 47.0 mg of DOTAP and 16.0 mg of DOPE, respectively) and the aqueous phase (4 mL of pure water and 90 mg of glycerol) were weighed and stirred at 70°C to completely dissolve. The aqueous phase was slowly dropped into the oil phase and mixed by magnetic stirring to form an emulsion. The prepared emulsion was homogenized in a high-speed homogenizer for 5 min at room temperature and ultrasonically emulsified for 3 min to obtain coix seed fat lipid nanoparticles.
[0068] Table 4: Particle size determination of lipid nanoparticles prepared with different weights of DOTAP
[0069] DOTAP(mg) Particle size (nm) PDI 15.2 580.4±10.8 0.80 33.0 195.2±3.9 0.18 47.0 375.4±6.2 0.69
[0070] As can be seen from the above table, in Example 4, the weight of DOTAP in the oil phase was changed to prepare coix seed lipid nanoparticles, and the oil phase formula condition was preferably DOTAP 33.0 mg according to the particle size for subsequent research.
[0071] Embodiment 5:
[0072] The oil phase (313.0 mg of coix seed fat, 33.0 mg of DOTAP and 2.5, 11.0 and 28.0 mg of DOPE, respectively) and the aqueous phase (4 mL of pure water and 90 mg of glycerol) were weighed and stirred at 70°C to completely dissolve. The aqueous phase was slowly dropped into the oil phase and mixed by magnetic stirring to form an emulsion. The prepared emulsion was homogenized in a high-speed homogenizer for 5 min at room temperature and ultrasonically emulsified for 3 min to obtain coix seed fat lipid nanoparticles.
[0073] Table 5: Particle size determination of lipid nanoparticles prepared with different weights of DOPE
[0074] DOPE(mg) Particle size (nm) PDI 2.5 249.0±3.5 0.20 11.0 156.6±2.2 0.17 28.0 362.8±6.2 0.18
[0075] As can be seen from the table above, in Example 5, the weight of DOPE in the oil phase was changed to prepare coix seed lipid nanoparticles. The oil phase formula condition was optimized according to the particle size, and DOPE 11.0 mg was used for subsequent research. The formula was determined as: coix seed lipid 313.0 mg, DOTAP 33.0 mg and DOPE 11.0 mg, and the appearance of the nanoparticles was observed by transmission electron microscopy. The results are shown in Figure 1 The obtained nanoparticles have uniform particle size.
[0076] Example 6: Preparation of PGA-LNP lipid nanoparticles
[0077] Weigh PGA and dissolve it in deionized water to prepare solutions with concentrations of 0.2, 0.5, and 2 g / L, respectively. Take 1 mL of PGA solution of different concentrations in a round-bottom flask, drop 0.1 mL of cationic lipid nanoparticles into the PGA solution, and stir magnetically for 5 minutes to obtain PGA-LNP lipid nanoparticles.
[0078] Table 6: Particle size and potential determination of different formulations
[0079] PGA(g / L) Particle size (nm) PDI Potential (mV) 2 180.8±3.9 0.22 -50.1±1.5 0.5 167.2±2.3 0.18 -34.5±1.8 0.2 154.2±0.2 0.21 45.0±3.5
[0080] As can be seen from the above table, according to the charge and particle size, PGA 0.5g / L was selected as the appropriate concentration to prepare nanoparticles for subsequent research.
[0081] Example 7: Preparation of PGA-LNP lipid nanoparticles
[0082] Weigh PGA and dissolve it in deionized water to prepare solutions with a concentration of 0.5 g / L. Take 1 mL of PGA solutions of different concentrations in a round-bottom flask, drop 0.1, 0.2 and 0.4 mL of cationic lipid nanoparticles into the PGA solution, stir magnetically for 5 minutes, and obtain PGA-LNP lipid nanoparticles. PGA-LNP is stored in a refrigerator at 4°C.
[0083] Table 7: Particle size and potential determination of different formulations
[0084] Cationic lipid nanoparticles (mL) Particle size (nm) PDI Potential (mV) 0.1 167.2±2.3 0.18 -34.5±1.8 0.2 233.6±2.3 0.17 -23.0±2.4 0.4 238.5±2.4 0.22 60.0±1.4
[0085] As can be seen from the table above, according to the charge and particle size, 0.1 mL of cationic lipid nanoparticles were preferably dropped into the PGA solution to prepare nanoparticles at an appropriate concentration for subsequent research. The appearance and morphology of the nanoparticles were observed using a transmission electron microscope. The results are shown in Figure 2 The obtained nanoparticles have uniform particle size, and PGA-LNP has an obvious core-shell structure, with a PGA layer wrapped on the outside, spherical, and irregular nanoemulsion loaded inside.
[0086] Example 8: Binding experiment of coix seed lipid nanoparticles and nucleic acid drug molecules
[0087] In vitro lipid nanoparticles and KRAS G12D siRNA (siKRAS G12D ) or NC siRNA (siNC) with an N / P ratio of 0.5:1, 1:1 and 2:1. 20 μL of lipid nanoparticle solution was diluted to the corresponding concentration with DEPC H2O in each tube. Only DEPC H2O was added to the control group. All were added to a 200 μL EEP tube without enzyme, and 20 μL of siRNA was added and gently mixed. The mixture was incubated at room temperature for 30 min to form lipid nanoparticle / nucleic acid drug molecule complexes.
[0088] Weigh 0.5g of 1% low-melting-point agarose powder and add it to a conical flask. Pour 25mL of 1×TAE solution into the conical flask, mix thoroughly and heat in a microwave for 1min. Repeat heating 3 times until the liquid boils and dissolves. Take it out and let it warm, add 2.5μL Gel-Red (10000×), mix well and pour into a flat plate, insert a comb, cool for 30min and then take out the comb to complete the gel preparation. Place the agar gel plate in the electrophoresis pool, add 1×TAE solution to cover the agar plate, add 2μL 10×Loading Buffer to the prepared free siRNA and lipid nanoparticle / nucleic acid drug molecule complexes and mix, add the sample to the agar gel plate, and perform electrophoresis at 120V, 400mA for 10-15min. Use gel imaging for development and take pictures. Figure 3 As shown, when N / P is 1:1, there is still an obvious free siRNA band, indicating that the complex is not completely formed at this ratio, while when N / P is 2:1, no free siRNA band appears. The results show that the nucleic acid drug molecules have been completely bound to the lipid nanoparticles.
[0089] Example 9: Cellular uptake experiment
[0090] AsPC-1 cells in the logarithmic growth phase were cultured at 10 4The cells were inoculated into a cell slide at a density of 100 cells and cultured in an incubator for 24 hours. The culture medium was discarded 4 hours before administration and Opti-MEM culture medium was added for pretreatment. Lipofectamine RNAiMAX (Lipo) was used to prepare Lipo / FAM-siRNA complexes according to the instructions.
[0091] DEPC H2O, lipid nanoparticles and Lipo solution were added to the same concentration of FAM-siRNA solution, and Opti-MEM medium was diluted for use. Opti-MEM medium, free FAM-siRNA, PGA-LNP / FAM-siRNA or Lipo / FAM-siRNA culture medium (200nM siRNA in each group) were added to the slides, respectively, and incubated in a cell culture incubator for 6 hours. Then the drug-containing medium was removed, and the cells were washed 3 times with PBS (pH 7.4), and then fixed with 4% paraformaldehyde (PFA) at room temperature for 10 minutes. Then the 4% PFA was removed, and the cells were washed 3 times with PBS, and then 0.2μg / mL of 4',6-diamidino-2-phenylindole (DAPI) solution was added and placed at room temperature for 10 minutes, and then the DAPI solution was removed and washed 3 times with PBS again. The slides were taken out and sealed with anti-fluorescence quenching sealing solution, and the cell uptake of FAM-siRNA was observed using a laser confocal microscope. Among them, the excitation wavelength of DAPI Emission wavelength Excitation wavelength of FAM Emission wavelength
[0092] from Figure 4 It can be observed that in AsPC-1 cells, the fluorescence intensity of the LNP / FAM-siRNA group was significantly higher than that of the free FAM-siRNA group, and a large amount of FAM fluorescence signals were visible in the cells. At the same time, the fluorescence signal values of the LNP / FAM-siRNA and Lipo / FAM-siRNA groups were close, indicating that the transfection efficiency of lipid nanoparticles and Lipo was similar, and they could effectively deliver nucleic acid drug molecules into cells.
[0093] Example 10: Cellular lipid droplet co-localization experiment
[0094] AsPC-1 cells were cultured at 1×10 4 The cells were inoculated at a density of 100 cells / well in a 24-well plate and cultured in a 37°C, 5% CO2 incubator for 24 h. TM C 12The culture medium was stained for 16 hours and then discarded. The nanoparticle solution was mixed with the solution and placed at room temperature for minutes. The culture medium of free FAM-siRNA, PGA-LNP / FAM-siRNA or Lipo / FAM-siRNA was diluted with Opti-MEM medium, and the final concentration of FAM-siRNA was 200nM. The cells were co-cultured at 37°C for 6 hours and 12 hours, the culture medium was removed, and the cells were washed 3 times with PBS, fixed with 4% PFA, washed 3 times with pre-cooled PBS, incubated with 0.2μg / mL DAPI staining solution for 30 minutes, washed 3 times with PBS, stained with DiD working solution for 5 minutes and discarded, and washed 3 times with PBS. After sealing with PBS, the slides were observed using a laser confocal microscope. Among them, BODIPY TM C 12 The excitation wavelength Emission wavelength Excitation wavelength of DiD Emission wavelength
[0095] The results are as follows Figure 5 As shown in the figure, there is no obvious co-localization between siRNA and Lipo / FAM-siRNA at 6h and 12h of administration, and the Lipo vector cannot target lipid droplets in cells. LNP / FAM-siRNA did not achieve lipid droplet co-localization at 6h, but FAM-siRNA was enriched near lipid droplets and achieved lipid droplet co-localization at 12h. The results show that LNP / FAM-siRNA can target lipid droplets.
[0096] Example 11: Lysosomal escape experiment
[0097] AsPC-1 cells were cultured at 1×10 4 The density of cells / well was inoculated in a confocal dish and cultured in a 37°C, 5% CO2 incubator for 24 hours. Transfection was performed according to the method in step 4. Co-cultured with cells at 37°C for 6 hours and 12 hours, the culture medium was removed, the cells were washed three times with PBS, and then stained with lysosomal fluorescent probe Lyso-Tracker Red preheated at 37°C in a 37°C incubator for 30 minutes, after removing the probe, washed three times with PBS, stained with 1μg / mL Hoechst for 5 minutes and discarded, washed three times with PBS, stained with DiD working solution for 5 minutes and discarded, washed three times with PBS, and observed under a laser confocal microscope. Among them, the excitation wavelength of Lyso-TrackerRed is Emission wavelength Figure 6At 6h, the fluorescence of FAM and lysosomes of the two preparations overlapped, indicating that the vector entered the lysosome through the endocytosis pathway. After 12h of administration of LNP / FAM-siRNA, green fluorescence appeared at the position indicated by the arrow when the fluorescence overlapped, indicating that the vector escaped from the lysosome and entered the cytoplasm. In contrast to LNP / FAM-siRNA, there was no green fluorescence in the Lipo / FAM-siRNA group at 12h when the fluorescence overlapped.
[0098] Example 12: Clone formation assay to detect the effect of lipid nanoparticles / nucleic acid drug molecules on cell proliferation
[0099] AsPC-1 cells were cultured at 1×10 3 The cells were seeded at a density of 100 cells / well in a 6-well plate and cultured in a 37°C, 5% CO2 incubator for 24 h. Blank culture medium, LNP / siKRAS G12D 、LNP / siNC、Lipo / siKRAS G12D and Lipo / siNC, 1 mL of each was added to different wells for transfection. After 6 hours of administration, the culture medium was discarded and fresh drug-free culture medium was added to continue culturing for 14 days, with the culture medium replaced every 3 days. After the formation of colonies visible to the naked eye, the old culture medium was discarded and the cells were washed 3 times with PBS, fixed with 4% PFA for 10 minutes, and 1 mL of 0.1% crystal violet stain was added to each well for staining for 10-20 minutes. The cells were washed several times with PBS, dried and photographed with a scanner. Figure 7 and Figure 8 As shown, LNP / siKRAS G12D and Lipo / siKRAS G12D Both can significantly affect KRAS G12D The proliferation of mutant AsPC-1 cells was significantly inhibited (P<0.01), but the proliferation of KRAS wild-type BxPC-3 cells was not affected. The clone capacity of AsPC-1 cells was not significantly affected in the lipid nanoparticle / siNC and Lipo / siNC groups, indicating that siKRAS G12D Lipid nanoparticles can effectively deliver siKRAS to inhibit the proliferation of AsPC-1 cells G12D And exert therapeutic effect.
[0100] Example 13: qRT-PCR detection of intracellular KRAS G12D Gene expression
[0101] AsPC-1 cells were cultured at 1×10 5 The cells were seeded at a density of 100 cells / well in a 6-well plate and cultured in a 37°C, 5% CO2 incubator for 24 h. Blank culture medium, LNP / siKRAS G12D、LNP / siNC、Lipo / siKRAS G12D 1 mL of each was added to different wells for transfection. After 6 hours of administration, the medium was discarded and fresh medium without drug was added to continue culturing for 42 hours. The medium containing drug was discarded and RNA was extracted from each group according to the qRT-PCR method to detect KRAS in cells. G12D Gene expression. Fig. 9 As shown, both formulations containing negative control siNCs were positive for KRAS G12D There was almost no effect on gene expression. G12D Comparison, LNP / siKRAS G12D There was no significant difference in gene expression levels between the two groups, and both groups could significantly downregulate KRAS G12D Gene expression,
[0102] Example 14: Western blot detection of KRAS in cells G12D Protein expression
[0103] AsPC-1 cells were cultured at 1×10 5 The cells were seeded at a density of 100 cells / well in a 6-well plate and cultured in a 37°C, 5% CO2 incubator for 24 h. Blank culture medium, LNP / siKRAS G12D 、LNP / siNC、Lipo / siKRAS G12D 1 mL of each was added to different wells for transfection. After 6 hours of administration, the medium was discarded and fresh medium without drug was added to continue culturing for 42 hours. The medium containing drug was discarded and each group of proteins was extracted according to the Western blot method to detect KRAS in cells. G12D Protein expression. Fig.10 As shown, LNP / siKRAS G12D Can significantly reduce KRAS in AsPC-1 G12D of protein expression.
[0104] Example 15: In vivo fluorescence imaging to investigate the targeting of LNP / FAM-siRNA in nude mice
[0105] An orthotopic tumor-bearing nude mouse model was constructed. Eighteen successfully tumor-bearing nude mice were randomly divided into six groups, with three mice in each group. FAM-siRNA or PGA-LNP / FAM-siRNA solution was injected intraperitoneally (siRNA dosage was 2 nmol / time). The mice were placed in a small animal in vivo imaging instrument at 6, 12, and 24 hours after administration to detect the FAM fluorescence signal (excitation emission ), and calculate the fluorescence signal distribution intensity of each organ of nude mice. Fig.11 and Fig.12 As shown, after 6, 12 and 24 h of administration, the fluorescence intensity of PGA-LNP / FAM-siRNA in the tumor was higher than that of free FAM-siRNA, and the uptake was strongest at 12 h, proving that PGA-LNP can better target siRNA to the tumor site.
[0106] As can be seen from the above examples, the present invention prepares a new type of lipid nanoparticles, which are prepared with coix seed lipid, a traditional Chinese medicine lipid, as the main component, and are prepared together with DOTAP, DOPE and water to obtain cationic lipid nanoparticles. The carrier can load nucleic acid drug molecules and effectively deliver them into cells, achieve lysosomal escape, and target the lipid droplet site. Compared with the positive Lipo reagent, the carrier has a similar transfection efficiency and loads siKRAS G12D Can effectively reduce KRAS G12D Mutant AsPC-1 cells Gene and protein expression, inhibiting cell proliferation. At the same time, the present invention uses PGA as a target head, which can further significantly improve the specific targeting of the vector in the pancreatic cancer site in vivo. The present invention provides a new strategy for the treatment of pancreatic cancer by nucleic acid delivery vectors, especially nucleic acid drug molecules, from the perspective of formulation.
Claims
1. A method for preparing coix seed lipid nanoparticles capable of loading nucleic acid drugs, characterized in that: The steps include: Weighing an oil phase and an aqueous phase, wherein the oil phase comprises 63.6-736.0 mg of coix seed fat, 15.2-47.0 mg of DOTAP and 2.5-28.0 mg of DOPE, and the aqueous phase comprises 4 mL of pure water and 90 mg of glycerol; The oil phase and the water phase are stirred at 70° C. to completely dissolve, and the water phase is slowly dripped into the oil phase and mixed by magnetic stirring to form an emulsion. The emulsion is homogenized with a high-speed homogenizer at room temperature for 1-10 minutes, and then ultrasonicated in an ultrasonic emulsifier for 1-5 minutes to obtain coix seed lipid nanoparticles.
2. A coix seed lipid nanoparticle capable of loading a nucleic acid drug, characterized in that: The coix seed lipid nanoparticles consist of an oil phase and a water phase, wherein the oil phase comprises 63.6-736.0 mg coix seed lipid, 15.2-47.0 mg DOTAP and 2.5-28.0 mg DOPE, and the water phase comprises 4 mL pure water and 90 mg glycerol.
3. The coix seed lipid nanoparticles capable of loading nucleic acid drugs according to claim 2, characterized in that: The coix seed fat lipid nanoparticles consist of an oil phase and a water phase, wherein the oil phase includes 313 mg coix seed fat, 33 mg DOTAP and 11 mg DOPE, and the water phase includes 4 mL pure water and 90 mg glycerol.
4. Use of the coix seed lipid nanoparticles capable of loading nucleic acid drugs as claimed in any one of claims 2 to 3 in the treatment of pancreatic cancer.
